Business Wire

UT-IFIT

13.7.2021 13:02:13 CEST | Business Wire | Press release

Share
iFIT Acquires Sweat, a Leading Digital Fitness App for Women

iFIT Health & Fitness Inc. (“iFIT”), a global leader in connected fitness software, content and equipment, today announced it has acquired Sweat, a leading platform for women's health and fitness. The acquisition of Sweat expands iFIT’s presence in the global digital fitness market, and accelerates the company’s delivery of best-in-class interactive fitness experiences for consumers worldwide. Sweat will remain a standalone brand as part of iFIT. Financial terms were not disclosed.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210713005441/en/

Founded in 2015 by renowned trainer Kayla Itsines and CEO Tobi Pearce, Sweat has engaged with millions of women around the world in their journeys to become healthier, stronger and more confident. The Sweat platform is powered by a team of industry-leading personal trainers and offers over 5,000 unique workouts across 26 exercise programs ranging from high-intensity interval training and strength to yoga, barre and Pilates. Sweat Co-Founders Kayla Itsines and Tobi Pearce will continue to lead the Sweat business in their existing roles, with the company remaining headquartered in Adelaide, Australia.

Working with the Sweat team, iFIT will use its over four decades of experience and innovation in the connected fitness space to strengthen the Sweat member experience, build brand presence in key international markets, and grow and diversify content offerings, including the introduction of cardio-based and equipment workouts in the coming months. The acquisition will also provide opportunities for iFIT and Sweat to collaborate on content development, resulting in an increased range of exciting fitness experiences. iFIT plans to support job growth in the Sweat business over the near- and long-term across product, engineering, marketing and content divisions.

“Kayla, Tobi and the team at Sweat have built an incredible brand and community of fitness enthusiasts,” said Scott Watterson, CEO and Founder of iFIT. “We are delighted to welcome Kayla’s authentic fitness training and charismatic personality—along with all of Sweat’s other star trainers—to the iFIT family.”

“Our two founder-led businesses are highly complementary and this acquisition extends our market reach into new geographies, demographics and fitness preferences spanning both home and commercial markets globally. We have a shared vision of helping people around the world achieve their goals for health and well-being.”

Watterson added, “The addition of Sweat will allow iFIT to further expand our membership base as well as add new fitness genres and modalities to our fast-growing subscription business, giving our company a tremendous competitive advantage.”

“We have long admired iFIT as a fitness industry leader and are proud to join the iFIT family,” said Sweat CEO and Co-Founder Tobi Pearce. “We look forward to working with Scott and his leadership team to accelerate our global expansion and further enhance the consumer experience for Sweat as part of the iFIT ecosystem. iFIT enables us to create a breadth of engaging new content to fulfill the rapidly growing fitness needs of our members around the world.”

Sweat Co-Founder Kayla Itsines said the acquisition represented a new chapter in the company’s history.

“Sweat has had an incredible journey from our humble beginnings training women one-on-one in my Adelaide backyard to launching the Sweat App in 2015 to now joining the iFIT family,” Itsines said. “Sweat was founded on our simple belief that fitness can genuinely help women improve their confidence, health and quality of life. Through iFIT’s strategic leadership, we will be able to create new world class fitness content and product experiences to support more women on their fitness path forward.”

“IFIT’s acquisition has opened the door to an exciting new future for Sweat where we can deliver greater fitness variety, choice and value for women everywhere.”

About iFIT Health & Fitness

iFIT Health & Fitness is a global health and fitness technology company that provides unmatched fitness experiences and solutions to its growing community of millions of engaged members across 120 countries. iFIT’s industry-leading brands – NordicTrack®, ProForm® and Freemotion® – are powered by the iFIT integrated health and fitness platform, which seamlessly connects the company’s proprietary software, experiential content and interactive hardware. Based in Logan, Utah, with offices in Paris, Shanghai, Melbourne, and Manchester, the company offers immersive, adaptive, personalized workout experiences for every fitness level and interest. iFIT delivers these patented interactive experiences through an extensive offering of live and on-demand content across a full range of fitness modalities.

About Sweat

The Sweat app is one of the world’s largest digital fitness training platforms for women. Founded in 2015, the category leading app gives women affordable and on-demand access to expert fitness advice, one-on-one personal training and unique exercise content that is made by women, for women. With 26 unique workout programs powered by a team of 13 female trainers led by Co-Founder Kayla Itsines, Sweat has built a global community of more than 50 million women across its social channels offering support and inspiration to help women reach their fitness goals. The Sweat app is translated into eight different languages and is available in 155 countries.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye